Immunotherapeutic compositions for the treatment of Alzheimer's disease

An immunotherapeutic composition for the treatment of Alzheimer's disease comprising:

• an immunogen comprising a peptide, said peptide comprising an amino acid sequence of 7-15 consecutive amino acid residues of human amyloid beta protein 1-42 conjugated to an immunogenic carrier protein, formulated in a water-in-oil emulsion with an oily adjuvant vehicle comprising squalene, squalane and mannide monooleate, and polyoxyl-40-hydrogenated castor oil, wherein the immunogen is contained within aqueous globules that have a median diameter from about 100 nanometers to about 1 micron;
• wherein:
• the immunogenic carrier protein is diphtheria toxoid carrier;
• the immunogen has a conjugation ratio of moles of peptide per mole of carrier of from about 5:1 to about 30:1;
• the oily adjuvant vehicle comprises from about 85% to about 90% squalene and squalane, from about 9% to about 12% mannide monooleate and from about 0.5% to about 0.7% polyoxyl 40-hydrogenated castor oil;
• and
• the peptide comprising the amino acid sequence of human amyloid beta protein is coupled to the immunogenic carrier protein via a spacer.